

Midazolam in Sodium Chloride Injection 1 mg/ml (50 mg/50 ml & 100 mg/100 ml bags)

Safety Data Sheet

According To Federal Register / Vol. 89, No. 98 / Monday, May 20, 2024 / Rules And Regulations And According To The Hazardous Products Regulation (December 15, 2022).

Date of Issue: 03/06/2025

Version: 1.0

SECTION 1: IDENTIFICATION

1.1. Product Identifier

Product Form: Mixture

Product Name: Midazolam in Sodium Chloride Injection 1 mg/ml (50 mg/50 ml & 100 mg/100 ml bags)

1.2 Recommended Use and Restrictions on Use

Use of the Substance/Mixture: The following SDS applies only to formulated Midazolam in bags and standard shipments of these bags. If handling Midazolam in sodium chloride Injection, in manufacturing situations, consult the SDS for the active ingredient and take appropriate precautions. For Intravenous use.

Restrictions on use:

1.3. Name, Address, and Telephone of the Responsible Party

Distributor

Fresenius Kabi USA, LLC

Three Corporate Drive

Lake Zurich, IL 60047

General Phone Number: (847) 550-2300

Customer Service Phone Number: (888) 386-1300

Health Issues Information: (800) 551-7176

<http://www.fresenius-kabi.com/us/>

1.4. Emergency Telephone Number

Emergency Number : VelocityEHS
(800)255-3924 (North America)
+1 (813)248-0585 (International)

SECTION 2: HAZARDS IDENTIFICATION

2.1. Classification of the Substance or Mixture

GHS-US/CA Classification

Skin corrosion/irritation, Category 2 H315

Serious eye damage/eye irritation, Category 2 H319

2.2. Label Elements

GHS-US/CA Labeling

Hazard Pictograms (GHS-US/CA) :



GHS07

Signal Word (GHS-US/CA) : Warning

Hazard Statements (GHS-US/CA) : H315 - Causes skin irritation.

H319 - Causes serious eye irritation.

Precautionary Statements (GHS-US/CA) : P264 - Wash hands, forearms and face thoroughly after handling.
P280 - Wear protective gloves, protective clothing, eye protection, face protection, and hearing protection.
P302+P352 - IF ON SKIN: Wash with plenty of water.
P305+P351+P338 - IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P321 - Specific treatment (see supplemental first aid instruction on this label).
P332+P313 - If skin irritation occurs: Get medical advice or attention.
P337+P313 - If eye irritation persists: Get medical advice or attention.
P362+P364 - Take off contaminated clothing and wash it before reuse.

Midazolam in Sodium Chloride Injection 1 mg/ml (50 mg/50 ml & 100 mg/100 ml bags)

Safety Data Sheet

According To Federal Register / Vol. 89, No. 98 / Monday, May 20, 2024 / Rules And Regulations And According To The Hazardous Products Regulation (December 15, 2022).

2.3 Hazards associated with known or reasonably anticipated uses

No additional information available

2.4. Other Hazards

Exposure may aggravate pre-existing eye, skin, or respiratory conditions.

2.4. Unknown Acute Toxicity (GHS-US/CA)

No additional information available

SECTION 3: COMPOSITION/INFORMATION ON INGREDIENTS

3.1. Substance

Not applicable

3.2. Mixture

Name	Synonyms	Product Identifier	% *	GHS Ingredient Classification
Water	AQUA	(CAS-No.) 7732-18-5	97.4	Not classified.
Sodium chloride	Sea salt / Sodium chloride (NaCl) / SODIUM CHLORIDE / Sodium salt of hydrochloric acid / Salt / SEA SALT	(CAS-No.) 7647-14-5	0.1 – 1	Not classified.
Hydrochloric acid	Hydrogen chloride / Muriatic acid / HYDROCHLORIC ACID / Hydrochloric acid, anhydrous	(CAS-No.) 7647-01-0	0.1 – 1	Met. Corr. 1, H290 Skin Corr. 1A, H314 Eye Dam. 1, H318 STOT SE 3, H335 Aquatic Acute 2, H401
Midazolam	4H-Imidazo(1,5-a)(1,4)benzodiazepine, 8-chloro-6-(2-fluorophenyl)-1-methyl- / 8-Chloro-6-(o-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4]benzodiazepine / 4H-Imidazo[1,5-a][1,4]benzodiazepine, 8-chloro-6-(2-fluorophenyl)-1-methyl- / 8-Chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4]benzodiazepine / midazolam / 8-Chloro-6-(o-fluorophenyl)-1-methyl-4H-imidazo[1,5- .alfa.][1,4]benzodiazepine	(CAS-No.) 59467-70-8	< 0.5	Acute Tox. 3 (Oral), H301 Aquatic Chronic 2, H411
Sodium hydroxide	Caustic soda / Sodium hydroxide (NaOH) / SODIUM HYDROXIDE / LYE / Lye solution	(CAS-No.) 1310-73-2	< 0.1	Met. Corr. 1, H290 Acute Tox. 4 (Oral), H302 Skin Corr. 1, H314 Eye Dam. 1, H318 Aquatic Acute 3, H402

Full text of H-statements: see section 16

* The actual concentration of ingredient(s) is withheld as a trade secret in accordance with the Hazardous Products Regulations (HPR) SOR/2015-17 and 29 CFR 1910.1200. Percentages are listed in weight by weight percentage (w/w%) for liquid and solid ingredients. Gas ingredients are listed in volume by volume percentage (v/v%). Full text of H-statements: see section 16.

SECTION 4: FIRST AID MEASURES

4.1. Description of First-aid Measures

General: Never give anything by mouth to an unconscious person. If you feel unwell, seek medical advice (show the label where possible).

Inhalation: When symptoms occur: go into open air and ventilate suspected area. Obtain medical attention if breathing difficulty persists.

Midazolam in Sodium Chloride Injection 1 mg/ml (50 mg/50 ml & 100 mg/100 ml bags)

Safety Data Sheet

According To Federal Register / Vol. 89, No. 98 / Monday, May 20, 2024 / Rules And Regulations And According To The Hazardous Products Regulation (December 15, 2022).

Skin Contact: Remove contaminated clothing. Immediately drench affected area with water for at least 15 minutes. Obtain medical attention if irritation develops or persists.

Eye Contact: Immediately rinse with water for at least 15 minutes. Remove contact lenses, if present and easy to do. Continue rinsing. Obtain medical attention if irritation develops or persists.

Ingestion: Rinse mouth. Do NOT induce vomiting. Obtain medical attention.

4.2. Most Important Symptoms and Effects Both Acute and Delayed

General: Causes skin irritation. Causes serious eye irritation.

Inhalation: Prolonged exposure may cause irritation.

Skin Contact: Redness, pain, swelling, itching, burning, dryness, and dermatitis.

Eye Contact: Contact causes severe irritation with redness and swelling of the conjunctiva.

Ingestion: Ingestion may cause adverse effects.

Chronic Symptoms: None known.

4.3. Indication of Any Immediate Medical Attention and Special Treatment Needed

If exposed or concerned, get medical advice and attention. If medical advice is needed, have product container or label at hand.

SECTION 5: FIRE-FIGHTING MEASURES

5.1. Extinguishing Media

Suitable Extinguishing Media: Water spray, fog, carbon dioxide (CO₂), alcohol-resistant foam, or dry chemical.

Unsuitable Extinguishing Media: Do not use a heavy water stream. Use of heavy stream of water may spread fire.

5.2. Special Hazards Arising From the Substance or Mixture

Fire Hazard: Not considered flammable but may burn at high temperatures.

Explosion Hazard: Product is not explosive.

Reactivity: Hazardous reactions will not occur under normal conditions.

5.3. Advice for Firefighters

Precautionary Measures Fire: Exercise caution when fighting any chemical fire.

Firefighting Instructions: Use water spray or fog for cooling exposed containers.

Protection During Firefighting: Do not enter fire area without proper protective equipment, including respiratory protection.

Hazardous Combustion Products: Carbon oxides, Nitrogen oxides. Chlorides. Fluorine compounds. Sodium oxides.

5.4. Reference to Other Sections

Refer to Section 9 for flammability properties.

SECTION 6: ACCIDENTAL RELEASE MEASURES

6.1. Personal Precautions, Protective Equipment and Emergency Procedures

General Measures: Avoid breathing (vapor, mist, spray). Avoid all contact with skin, eyes, or clothing.

6.1.1. For Non-Emergency Personnel

Protective Equipment: Use appropriate personal protective equipment (PPE).

Emergency Procedures: Evacuate unnecessary personnel.

6.1.2. For Emergency Personnel

Protective Equipment: Equip cleanup crew with proper protection.

Emergency Procedures: Upon arrival at the scene, a first responder is expected to recognize the presence of dangerous goods, protect oneself and the public, secure the area, and call for the assistance of trained personnel as soon as conditions permit. Ventilate area.

6.2. Environmental Precautions

Prevent entry to sewers and public waters.

6.3. Methods and Materials for Containment and Cleaning Up

For Containment: Contain any spills with dikes or absorbents to prevent migration and entry into sewers or streams.

Methods for Cleaning Up: Clean up spills immediately and dispose of waste safely. Absorb and/or contain spill with inert material. Transfer spilled material to a suitable container for disposal. Contact competent authorities after a spill.

6.4. Reference to Other Sections

See Section 8 for exposure controls and personal protection and Section 13 for disposal considerations.

Midazolam in Sodium Chloride Injection 1 mg/ml (50 mg/50 ml & 100 mg/100 ml bags)

Safety Data Sheet

According To Federal Register / Vol. 89, No. 98 / Monday, May 20, 2024 / Rules And Regulations And According To The Hazardous Products Regulation (December 15, 2022).

SECTION 7: HANDLING AND STORAGE

7.1. Precautions for Safe Handling

Precautions for Safe Handling: Avoid contact with skin, eyes and clothing. Wash hands and other exposed areas with mild soap and water before eating, drinking or smoking and when leaving work. Avoid breathing vapors, mist, spray.

Hygiene Measures: Handle in accordance with good industrial hygiene and safety procedures.

7.2. Conditions for Safe Storage, Including Any Incompatibilities

Technical Measures: Comply with applicable regulations.

Storage Conditions: Keep container closed when not in use. Store in a dry, cool place. Keep/Store away from direct sunlight, extremely high or low temperatures and incompatible materials. Do not freeze.

Incompatible Materials: Strong acids, strong bases, strong oxidizers.

Storage Temperature: Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature]. Protect from Freezing.

7.3. Specific End Use(s)

The following SDS applies only to formulated Midazolam in bags and standard shipments of these bags. If handling Midazolam in sodium chloride Injection, in manufacturing situations, consult the SDS for the active ingredient and take appropriate precautions. For Intravenous use.

SECTION 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

8.1. Control Parameters

For substances listed in section 3 that are not listed here, there are no established exposure limits from the manufacturer, supplier, importer, or the appropriate advisory agency including: ACGIH (TLV), AIHA (WEEL), NIOSH (REL), OSHA (PEL), or Canadian provincial governments.

Hydrochloric acid (7647-01-0)		
USA ACGIH	ACGIH OEL C	2 ppm
USA ACGIH	ACGIH chemical category	Not Classifiable as a Human Carcinogen
USA OSHA	OSHA PEL C	7 mg/m ³
USA OSHA	OSHA PEL C	5 ppm
USA NIOSH	NIOSH REL C	7 mg/m ³
USA NIOSH	NIOSH REL C	5 ppm
USA IDLH	IDLH	50 ppm
Alberta	OEL C	3 mg/m ³
Alberta	OEL C	2 ppm
British Columbia	OEL C	2 ppm
Manitoba	OEL C	2 ppm
New Brunswick	OEL C	2 ppm
Newfoundland & Labrador	OEL C	2 ppm
Nova Scotia	OEL C	2 ppm
Nunavut	OEL C	2 ppm
Northwest Territories	OEL C	2 ppm
Ontario	OEL C	2 ppm
Prince Edward Island	OEL C	2 ppm
Québec	Plafond (OEL C)	2 ppm
Saskatchewan	OEL C	2 ppm
Yukon	OEL C	7 mg/m ³
Yukon	OEL C	5 ppm
Sodium hydroxide (1310-73-2)		
USA ACGIH	ACGIH OEL C	2 mg/m ³
USA OSHA	OSHA PEL TWA	2 mg/m ³
USA NIOSH	NIOSH REL C	2 mg/m ³
USA IDLH	IDLH	10 mg/m ³
Alberta	OEL C	2 mg/m ³

Midazolam in Sodium Chloride Injection 1 mg/ml (50 mg/50 ml & 100 mg/100 ml bags)

Safety Data Sheet

According To Federal Register / Vol. 89, No. 98 / Monday, May 20, 2024 / Rules And Regulations And According To The Hazardous Products Regulation (December 15, 2022).

British Columbia	OEL C	2 mg/m ³
Manitoba	OEL C	2 mg/m ³
New Brunswick	OEL C	2 mg/m ³
Newfoundland & Labrador	OEL C	2 mg/m ³
Nova Scotia	OEL C	2 mg/m ³
Nunavut	OEL C	2 mg/m ³
Northwest Territories	OEL C	2 mg/m ³
Ontario	OEL C	2 mg/m ³
Prince Edward Island	OEL C	2 mg/m ³
Québec	Plafond (OEL C)	2 mg/m ³
Saskatchewan	OEL C	2 mg/m ³
Yukon	OEL C	2 mg/m ³

8.2. Exposure Controls

Appropriate Engineering Controls: Emergency eye wash fountains and safety showers should be available in the immediate vicinity of any potential exposure. Ensure adequate ventilation, especially in confined areas. Ensure all national/local regulations are observed.

Personal Protective Equipment: Gloves. Protective clothing. Protective goggles.



Materials for Protective Clothing: Chemically resistant materials and fabrics.

Hand Protection: Wear protective gloves.

Eye and Face Protection: Chemical safety goggles or safety glasses with side shields.

Skin and Body Protection: Wear suitable protective clothing.

Respiratory Protection: If exposure limits are exceeded or irritation is experienced, approved respiratory protection should be worn. In case of inadequate ventilation, oxygen deficient atmosphere, or where exposure levels are not known wear approved respiratory protection.

Other Information: When using, do not eat, drink or smoke.

SECTION 9: PHYSICAL AND CHEMICAL PROPERTIES

9.1. Information on Basic Physical and Chemical Properties

Physical State	: Liquid
Color	: Clear, colorless solution
Odor	: Characteristics
Odor Threshold	: No data available
pH	: 2.5 – 3.5
Evaporation Rate	: No data available
Melting Point	: No data available
Freezing Point	: No data available
Boiling Point	: No data available
Flash Point	: No data available
Auto-ignition Temperature	: No data available
Decomposition Temperature	: No data available
Flammability (solid, gas)	: Not applicable
Lower Flammable Limit	: No data available
Upper Flammable Limit	: No data available
Vapor Pressure	: No data available
Relative Vapor Density at 20°C	: No data available
Relative Density	: No data available
Specific Gravity	: No data available

Midazolam in Sodium Chloride Injection 1 mg/ml (50 mg/50 ml & 100 mg/100 ml bags)

Safety Data Sheet

According To Federal Register / Vol. 89, No. 98 / Monday, May 20, 2024 / Rules And Regulations And According To The Hazardous Products Regulation (December 15, 2022).

Solubility	: Water: The hydrochloride salt of midazolam, which is formed in situ, is soluble in aqueous solutions.
Partition Coefficient: N-Octanol/Water	: No data available
Viscosity, Kinematic	: No data available
Particle Aspect Ratio	: Not applicable
Particle Aggregation State	: Not applicable
Particle Agglomeration State	: Not applicable
Particle Specific Surface Area	: Not applicable
Particle Dustiness	: Not applicable

SECTION 10: STABILITY AND REACTIVITY

10.1. Reactivity:	Hazardous reactions will not occur under normal conditions.
10.2. Chemical Stability:	Stable under recommended handling and storage conditions (see section 7).
10.3. Possibility of Hazardous Reactions, Including those Associated with Foreseeable Emergencies:	Hazardous polymerization will not occur.
10.4. Conditions to Avoid:	Direct sunlight, extremely high or low temperatures, and incompatible materials.
10.5. Incompatible Materials:	Strong acids, strong bases, strong oxidizers.
10.6. Hazardous Decomposition Products:	Thermal decomposition may produce: Carbon oxides, Nitrogen oxides. Chlorides. Fluorine compounds. Sodium oxides.

SECTION 11: TOXICOLOGICAL INFORMATION

11.1. Information on Toxicological Effects - Product	
Acute Toxicity (Oral):	Not classified.
Acute Toxicity (Dermal):	Not classified.
Acute Toxicity (Inhalation):	Not classified.
LD50 and LC50 Data:	No additional information available
Skin Corrosion/Irritation:	Causes skin irritation.
pH:	2.5 – 3.5
Eye Damage/Irritation:	Causes serious eye irritation.
pH:	2.5 – 3.5
Respiratory or Skin Sensitization:	Not classified.
Germ Cell Mutagenicity:	Not classified.
Carcinogenicity:	Not classified.
Specific Target Organ Toxicity (Repeated Exposure):	Not classified.
Reproductive Toxicity:	Not classified.
Specific Target Organ Toxicity (Single Exposure):	Not classified.
Aspiration Hazard:	Not classified.
Symptoms/Injuries After Inhalation:	Prolonged exposure may cause irritation.
Symptoms/Injuries After Skin Contact:	Redness, pain, swelling, itching, burning, dryness, and dermatitis.
Symptoms/Injuries After Eye Contact:	Contact causes severe irritation with redness and swelling of the conjunctiva.
Symptoms/Injuries After Ingestion:	Ingestion may cause adverse effects.
Chronic Symptoms:	None known.
11.2. Information on Toxicological Effects - Ingredient(s)	
LD50 and LC50 Data:	
Midazolam (59467-70-8)	
LD50 Oral Rat	215 mg/kg (Source: NLM_CIP)
Sodium chloride (7647-14-5)	
LD50 Oral Rat	3550 mg/kg (Species: Wistar)

Midazolam in Sodium Chloride Injection 1 mg/ml (50 mg/50 ml & 100 mg/100 ml bags)

Safety Data Sheet

According To Federal Register / Vol. 89, No. 98 / Monday, May 20, 2024 / Rules And Regulations And According To The Hazardous Products Regulation (December 15, 2022).

LD50 Dermal Rabbit	> 10000 mg/kg (Species: New Zealand White)
LC50 Inhalation Rat	> 42 mg/l (Exposure time: 1 h Source: ECHA_API)
Hydrochloric acid (7647-01-0)	
LD50 Oral Rat	238 – 277 mg/kg (Source: JAPAN_GHS)
LD50 Dermal Rabbit	> 5010 mg/kg (Source: JAPAN_GHS)
LC50 Inhalation Rat	1.68 mg/l (Exposure time: 1 h Source: JAPAN_GHS)
Sodium hydroxide (1310-73-2)	
LD50 Oral Rat	325 mg/kg
LD50 Dermal Rabbit	1350 mg/kg (Source: NLM_HSDB)
Water (7732-18-5)	
LD50 Oral Rat	> 90 ml/kg (Source: FOOD_JOURN)
Hydrochloric acid (7647-01-0)	
IARC Group	3

SECTION 12: ECOLOGICAL INFORMATION

12.1. Toxicity

Ecology - General: Not classified.

Sodium chloride (7647-14-5)	
LC50 Fish 1	5560 (5560 – 6080) mg/l (Exposure time: 96 h - Species: Lepomis macrochirus [flow-through])
EC50 - Crustacea [1]	1000 mg/l (Exposure time: 48 h - Species: Daphnia magna)
LC50 Fish 2	12946 mg/l (Exposure time: 96 h - Species: Lepomis macrochirus [static] Source: EPA)
EC50 - Crustacea [2]	340.7 (340.7 – 469.2) mg/l (Exposure time: 48 h - Species: Daphnia magna [Static])
NOEC Chronic Fish	252 mg/l (Species: Pimephales promelas)
Hydrochloric acid (7647-01-0)	
LC50 Fish 1	7.45 mg/l (Species: Oncorhynchus mykiss - Exposure time: 96h)
Sodium hydroxide (1310-73-2)	
LC50 Fish 1	45.4 mg/l (Exposure time: 96 h - Species: Oncorhynchus mykiss [static])
EC50 - Crustacea [1]	40 mg/l

12.2. Persistence and Degradability

Midazolam in Sodium Chloride Injection 1 mg/ml (50 mg/50 ml & 100 mg/100 ml bags)	
Persistence and Degradability	Not established.

12.3. Bioaccumulative Potential

Midazolam in Sodium Chloride Injection 1 mg/ml (50 mg/50 ml & 100 mg/100 ml bags)	
Bioaccumulative Potential	Not established.
Sodium chloride (7647-14-5)	
BCF Fish 1	(no bioaccumulation)

12.4. Mobility in Soil

No additional information available

12.5. Other Adverse Effects

Other Information: Avoid release to the environment.

SECTION 13: DISPOSAL CONSIDERATIONS

13.1. Waste treatment methods

Waste Disposal Recommendations: Dispose of contents/container in accordance with local, regional, national, territorial, provincial, and international regulations.

Ecology - Waste Materials: Avoid release to the environment.

SECTION 14: TRANSPORT INFORMATION

The shipping description(s) stated herein were prepared in accordance with certain assumptions at the time the SDS was authored, and can vary based on a number of variables that may or may not have been known at the time the SDS was issued.

Midazolam in Sodium Chloride Injection 1 mg/ml (50 mg/50 ml & 100 mg/100 ml bags)

Safety Data Sheet

According To Federal Register / Vol. 89, No. 98 / Monday, May 20, 2024 / Rules And Regulations And According To The Hazardous Products Regulation (December 15, 2022).

14.1. In Accordance with DOT

Not regulated for transport

14.2. In Accordance with IMDG

Not regulated for transport

14.3. In Accordance with IATA

Not regulated for transport

14.4. In Accordance with TDG

Not regulated for transport

SECTION 15: REGULATORY INFORMATION

15.1. US Federal Regulations

Midazolam in Sodium Chloride Injection 1 mg/ml (50 mg/50 ml & 100 mg/100 ml bags)

SARA Section 311/312 Hazard Classes	Health hazard - Skin corrosion or Irritation
	Health hazard - Serious eye damage or eye irritation

Sodium chloride (7647-14-5)

Listed on the United States TSCA (Toxic Substances Control Act) inventory - Status: Active

Hydrochloric acid (7647-01-0)

Listed on the United States TSCA (Toxic Substances Control Act) inventory - Status: Active

Listed on the United States SARA Section 302

Subject to reporting requirements of United States SARA Section 313

CERCLA RQ	5000 lb
SARA Section 302 Threshold Planning Quantity (TPQ)	500 lb (gas only)
SARA Section 313 - Emission Reporting	1 % (acid aerosols including mists, vapors, gas, fog, and other airborne forms of any particle size)

Sodium hydroxide (1310-73-2)

Listed on the United States TSCA (Toxic Substances Control Act) inventory - Status: Active

CERCLA RQ	1000 lb
-----------	---------

Water (7732-18-5)

Listed on the United States TSCA (Toxic Substances Control Act) inventory - Status: Active

15.2. US State Regulations

Hydrochloric acid (7647-01-0)

U.S. - New Jersey - Right to Know Hazardous Substance List
U.S. - Pennsylvania - RTK (Right to Know) List
U.S. - Massachusetts - Right To Know List
U.S. - Pennsylvania - RTK (Right to Know) - Environmental Hazard List

Sodium hydroxide (1310-73-2)

U.S. - New Jersey - Right to Know Hazardous Substance List
U.S. - Pennsylvania - RTK (Right to Know) List
U.S. - Massachusetts - Right To Know List
U.S. - Pennsylvania - RTK (Right to Know) - Environmental Hazard List

15.3. Canadian Regulations

Sodium chloride (7647-14-5)

Listed on the Canadian DSL (Domestic Substances List)

Hydrochloric acid (7647-01-0)

Listed on the Canadian DSL (Domestic Substances List)

Sodium hydroxide (1310-73-2)

Listed on the Canadian DSL (Domestic Substances List)

Water (7732-18-5)

Listed on the Canadian DSL (Domestic Substances List)

Midazolam in Sodium Chloride Injection 1 mg/ml (50 mg/50 ml & 100 mg/100 ml bags)

Safety Data Sheet

According To Federal Register / Vol. 89, No. 98 / Monday, May 20, 2024 / Rules And Regulations And According To The Hazardous Products Regulation (December 15, 2022).

SECTION 16: OTHER INFORMATION, INCLUDING DATE OF PREPARATION OR LAST REVISION

Date of Preparation or Latest Revision : 03/06/2025

Revision

Other Information : This document has been prepared in accordance with the SDS requirements of the OSHA Hazard Communication Standard 29 CFR 1910.1200 and Canada's Hazardous Products Regulations (HPR) SOR/2022-272.


GHS Full Text Phrases:

H315	Causes skin irritation
H319	Causes serious eye irritation

NFPA Health Hazard : 1 - Materials that, under emergency conditions, can cause significant irritation.

NFPA Fire Hazard : 0 - Materials that will not burn under typical fire conditions, including intrinsically noncombustible materials such as concrete, stone, and sand.

NFPA Reactivity Hazard : 0 - Material that in themselves are normally stable, even under fire conditions.



HMIS III Rating

Health : 2 Moderate Hazard

Flammability : 0 Minimal Hazard

Physical : 0 Minimal Hazard

Glossary of Data Source Abbreviations

ATSDR: Agency for Toxic Substances and Disease Registry (U.S. Department of Health and Human Services)

AU_WES: Australia WES

CHEMVIEW: ChemView (U.S. Environmental Protection Agency)

EC_RAR: European Commission Renewal Assessment Report

EC_SCOEL: European Commission Scientific Committee on Occupational Exposure Limits

ECETOC: European Centre for Ecotoxicology and Toxicology of Chemicals Reports

ECHA_API: European Chemicals Agency API

ECHA_RAC: ECHA Committee for Risk Assessment

EFSA: European Food Safety Authority

EPA: U.S. Environmental Protection Agency

EPA_AEGL: Acute Exposure Guideline Levels (U.S. Environmental Protection Agency)

EPA_FIFRA: Federal Insecticide, Fungicide, and Rodenticide Act Reregistration Eligibility Decision (U.S. Environmental Protection Agency)

EPA_HPV: High Production Volume Chemicals (U.S. Environmental Protection Agency)

EPA_TRED: Risk Assessment for Tolerance Reassessment Eligibility Decision (U.S. Environmental Protection Agency)

EU_CLH: European Union Harmonised Classification and Labelling Proposal

EU_RAR: European Union Risk Assessment Report

FOOD_JOURN: Food Research Journal (1956)

IARC: The International Agency for Research on Cancer

IDLH: National Institute for Occupational Health and Safety Immediately Dangerous to Life or Health Value Profiles

IUCLID: International Uniform Chemical Information Database

JAPAN_GHS: Japan GHS Basis for Classification Data

JP_J-CHECK: Japan J-Check

KR_NIER: South Korea National Institute of Environmental Research Evaluations

NICNAS: Australia National Industrial Chemicals Notification and Assessment Scheme

NIOSH: National Institute for Occupational Health and Safety (U.S. Department of Health and Human Services)

NLM_CIP: National Library of Medicine ChemID plus database

NLM_HSDB: National Library of Medicine Hazardous Substance Data Bank

NLM_PUBMED: National Library of Medicine PubMed database

NTP: National Toxicology Program

NZ_CCID: New Zealand Chemical Classification and Information Database

OECD_EHSP: Environment, Health, and Safety Publication (Organisation for Economic Co-operation and Development)

OECD_SIDS: Screening Information Data Sets (Organisation for Economic Co-operation and Development)

WHO: World Health Organization

This information is based on our current knowledge and is intended to describe the product for the purposes of health, safety and environmental requirements only. It should not therefore be construed as guaranteeing any specific property of the product.

NA GHS SDS 2024 (Can, US)